Last reviewed · How we verify

NCT02989467

Effects of Aprepitant on Satiation, Gastric Volume, Gastric Accommodation and Gastric Emptying

Completed Phase 1 Last updated 12 December 2018
What this trial tests

Phase 1 trial testing Aprepitant in Healthy in 27 participants. Completed in 1 January 2018.

Timeline
27 January 2017
Primary endpoint
20 November 2017
1 January 2018

Quick facts

Lead sponsorMayo Clinic
PhasePhase 1
StatusCompleted
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingtriple
Primary purposetreatment
Enrollment27
Start date27 January 2017
Primary completion20 November 2017
Estimated completion1 January 2018
Sites1 location across United States

Drugs / interventions tested

Conditions studied

Sponsor

Mayo Clinic

Who can join

Adults 18 to 65, any sex, with Healthy. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This research study is being done to compare the effects of Aprepitant and placebo on fasting gastric volume, accommodation volume, satiation (fullness) and gastric emptying.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other trials of Aprepitant

Trials testing the same drug.

Other recruiting trials for Healthy

Currently open trials in the same condition.

Other Mayo Clinic trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02989467.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing